Clinical trial · Observational
Genetic Polymorphisms in UGT1A6 and UGT2B7 in Asian Population: Association With Lung Cancer Phenotype
NCT00717353CI-TRIAL-00013460unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Primary 1. To determine the presence and frequency of novel and known UGT1A6 and UGT2B7 polymorphisms in healthy Chinese, Malay and Indian subjects. 2. To determine the presence and frequency of novel and known UGT1A6 and UGT2B7 polymorphisms in Chinese lung cancer patients with squamous cell and adenocarcinoma subtype. 3. To analyze the functional variations in UGT1A6 and UGT2B7 polymorphisms. Secondary 1 To study the correlation of UGT1A6 and UGT2B7 polymorphisms with lung cancer type.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- 1
- description
- Lung cancer
Primary outcomes (0)
[]Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion criteria for stage I study * Subjects \>= 18 years old * Hemoglobin \>= 8g/dL, Total white cell counts \>3.0 x 103/μl * ECOG =0 Inclusion criteria for stage II study * Chinese ethnicity * Patients \>18 years old * Hemoglobin =\> 8g/dL, Total white cell counts \>3.0 x 103/μl * Histologically or cytologically confirmed lung cancer for stage II study * Uncontrolled medical conditions such as diabetes, hypertension and coronary artery disease. Exclusion criteria * Histology of small cell lung cancer * Medical or psychiatric conditions which may impair the patient's ability to provide informed consent.
References
Publications (2)
- BACKGROUNDDesai AA, Innocenti F, Ratain MJ. UGT pharmacogenomics: implications for cancer risk and cancer therapeutics. Pharmacogenetics. 2003 Aug;13(8):517-23. doi: 10.1097/01.fpc.0000054116.14659.e5. PMID 12893990
- BACKGROUNDSaeki M, Saito Y, Jinno H, Tanaka-Kagawa T, Ohno A, Ozawa S, Ueno K, Kamakura S, Kamatani N, Komamura K, Kitakaze M, Sawada J. Single nucleotide polymorphisms and haplotype frequencies of UGT2B4 and UGT2B7 in a Japanese population. Drug Metab Dispos. 2004 Sep;32(9):1048-54. PMID 15319348